Catalyst Pharmaceutical CPRX Firdapse — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Catalyst Pharmaceutical in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Catalyst Pharmaceutical’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Catalyst Pharmaceutical's firdapse — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Catalyst Pharmaceutical's firdapse — revenue?
- Catalyst Pharmaceutical (CPRX) reported firdapse — revenue of $98.86M in Q1 2026.
- How has Catalyst Pharmaceutical's firdapse — revenue changed year-over-year?
- Catalyst Pharmaceutical's firdapse — revenue increased by 18.1% year-over-year, from $83.73M to $98.86M.
- What is the long-term trend for Catalyst Pharmaceutical's firdapse — revenue?
- Over 4 years (2021 to 2025), Catalyst Pharmaceutical's firdapse — revenue has grown at a 26.9% compound annual growth rate (CAGR), from $138M to $358.38M.
- What does firdapse — revenue mean?
- This metric represents the total gross revenue generated from the sale of the company's primary pharmaceutical product, excluding any assessed taxes collected on behalf of third parties. It serves as a key indicator of the product's market adoption, pricing power, and commercial success within its specific therapeutic area. Tracking this figure allows investors to evaluate the growth trajectory and revenue concentration of the company's flagship asset.